InnoManContiModPROJECT
LenioBio will contribute with a project titled »Innovative protein medicine biomanufacturing with Continuous-Modular ALiCE®«, and InnoManContiMod is a derivative of this title. The project will focus on further development of the cell-free protein expression system, ALiCE®, as an innovative, rapid and on-demand medicine manufacturing technology with strategic value for Europe, fitting into the mission of HERA.
LenioBio will be sharing more updates here as the project progresses to its next step, in line with the defined scope of work.
The key goal for the project includes the following:
- Scaling ALiCE® lysate production by optimising process yields, increasing batch size and transitioning to continuous manufacturing
- Expanding ALiCE® capabilities for targeted classes of protein medicines such as vaccines, multispecific antibodies and growth factors by engineering new functionalities and demonstrating modular protein production methods at scale
- Laying the groundwork for GMP-grade lysate production by establishing analytical qualifications, quality systems, and regulatory filing package
INNOVATIVE PROTEIN MEDICINE BIOMANUFACTURING WITH CONTINOUS-MODULAR ALiCE®
LenioBio secured a € 3.7 million EU4Health grant to advance ALiCE®, our proprietary cell-free protein expression system, as a rapid and on-demand manufacturing technology for protein-based medicines. This action grant comes from the European Commission’s Health Emergency Preparedness and Response Authority (HERA), with the aim to improve European resilience when faced with crises.
LenioBio is proud to contribute to this mission with ALiCE® and to further the cell-free biomanufacturing field.
“Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.“